Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Natera Inc
(NQ:
NTRA
)
106.61
+0.30 (+0.28%)
Streaming Delayed Price
Updated: 11:46 AM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Natera Inc
< Previous
1
2
3
4
5
6
Next >
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
January 09, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 29, 2023
From
Natera, Inc.
Via
Business Wire
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
December 27, 2023
From
Natera, Inc.
Via
Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 26, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
December 21, 2023
From
Natera, Inc.
Via
Business Wire
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
December 11, 2023
From
Natera, Inc.
Via
Business Wire
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
December 06, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Real-World Data Collaboration with Merck
November 14, 2023
From
Natera, Inc.
Via
Business Wire
Natera Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
November 08, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Participate in November Investor Conferences
November 07, 2023
From
Natera, Inc.
Via
Business Wire
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
November 03, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
November 02, 2023
From
Natera, Inc.
Via
Business Wire
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
October 22, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Report its Third Quarter 2023 Results on November 8
October 20, 2023
From
Natera, Inc.
Via
Business Wire
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
October 19, 2023
From
Natera, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
October 17, 2023
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
October 16, 2023
From
Natera, Inc.
Via
Business Wire
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
October 06, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
October 04, 2023
From
Natera, Inc.
Via
Business Wire
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
October 03, 2023
From
Natera, Inc.
Via
Business Wire
Natera Submits First PMA Module to the FDA for Signatera™
October 02, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Senior Leadership Appointments
September 18, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
September 14, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Pricing of $250 Million Follow-On Offering
September 07, 2023
From
Natera, Inc.
Via
Business Wire
Natera Launches Proposed Follow-On Offering
September 06, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Participate in Upcoming Investor Conferences
September 01, 2023
From
Natera, Inc.
Via
Business Wire
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
August 16, 2023
From
Natera, Inc.
Via
Business Wire
Natera Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Natera, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.